{
    "nct_id": "NCT00621010",
    "title": "A Phase 1 Single Escalating Dose Study to Assess the Safety and Pharmacokinetics of CTS21166 Administered Intravenously to Healthy Adult Males",
    "status": "COMPLETED",
    "last_update_time": "2008-07-07",
    "description_brief": "This study is the first human exposure for the drug candidate CTS21166 in healthy male volunteers",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "CTS21166 (aka ZPQ-21166) \u2014 BACE1 (beta\u2011secretase) inhibitor; small\u2011molecule"
    ],
    "placebo": [
        "Placebo (used in multiple cohorts of the Phase 1 study)"
    ],
    "explanation_target": [
        "Reason: The trial description and sponsor materials identify CTS21166 as an investigational agent for Alzheimer\u2019s disease and the first\u2011in\u2011human single ascending dose study in healthy males (NCT00621010). The Phase 1 record lists CTS21166 (ZPQ\u201121166) and shows multiple dose cohorts with placebo control. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Act: Web searches show CTS21166 is described in the literature and news releases as a beta\u2011secretase (BACE1) inhibitor \u2014 a small\u2011molecule designed to reduce production of amyloid\u2011beta (A\u03b2), i.e., targeting Alzheimer\u2019s pathological mechanism rather than only symptomatic cognitive enhancement. A review of BACE1 inhibitor drugs explicitly cites CTS21166 as the first BACE1 inhibitor to enter phase I and reports its pharmacodynamic effect on A\u03b2 reduction in human studies. \ue200cite\ue202turn0search5\ue202turn0search7\ue201",
        "Additional supporting details from trial records: NCT00621010 (CTS21166\u2011101) was sponsored by CoMentis, enrolled ~56 healthy adult males in single ascending IV dose cohorts (7.5 mg up to 225 mg) with placebo subjects in each cohort. The trial\u2019s primary purpose was safety/tolerability and PK. \ue200cite\ue202turn0search0\ue202turn0search4\ue201",
        "Reflect: Given CTS21166\u2019s documented mechanism (BACE1 inhibition) and its small\u2011molecule nature, the correct category is 'disease\u2011targeted small molecule' (targets Alzheimer\u2019s amyloid pathology). There is no evidence in the trial description that CTS21166 is a biologic, a purely symptomatic cognitive enhancer, or a neuropsychiatric symptom treatment. Chemical/compound listings further support small\u2011molecule identity. \ue200cite\ue202turn0search8\ue202turn0search5\ue201",
        "Web search results used: Clinical trial registry entries (NCT00621010 and related trial aggregator records) for study design and dosing; Science/press release noting CTS\u201121166 as a beta\u2011secretase inhibitor; and a PubMed Central review summarizing CTS21166 as an early BACE1 inhibitor with reported A\u03b2 reductions in humans. \ue200cite\ue202turn0search0\ue202turn0search7\ue202turn0search5\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: CTS21166 (also ZPQ-21166) is documented in clinical-trial records as a first\u2011in\u2011human, single ascending IV dose study (NCT00621010) for an investigational Alzheimer\u2019s agent; sponsor/trial listings identify the compound and dosing cohorts. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Act: Literature and trial summaries describe CTS21166 as a small\u2011molecule inhibitor of BACE1 (\u03b2\u2011site APP\u2011cleaving enzyme 1). BACE1 is the rate\u2011limiting protease that generates amyloid\u2011\u03b2 (A\u03b2) from APP, so BACE1 inhibition is a disease\u2011modifying approach that reduces A\u03b2 production \u2014 this maps directly to CADRO category A (Amyloid beta). Based on the explicit mechanism (BACE1 inhibition) and the trial\u2019s small\u2011molecule, disease\u2011targeted intent, the appropriate CADRO classification is A) Amyloid beta. \ue200cite\ue202turn0search3\ue202turn0search5\ue201",
        "Reflect: The trial description and external sources consistently identify CTS21166 as a BACE1 (\u03b2\u2011secretase) inhibitor aimed at reducing A\u03b2 production; there is no indication the intervention targets tau, inflammation, synaptic receptors, metabolism, or is a non\u2011therapeutic diagnostic. Therefore A) Amyloid beta is the best and most specific CADRO category (not multi\u2011target or Other). Supporting trial registry and literature search results are cited below. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Web search results used: \u2022 NCT00621010 / clinical trial record showing CTS21166 (ZPQ\u201121166), Phase 1 single ascending IV doses (safety/PK). \ue200cite\ue202turn0search0\ue201 \u2022 Trial aggregator/summary (MedPath) listing NCT00621010 details (cohorts, enrollment). \ue200cite\ue202turn0search1\ue201 \u2022 Reviews and publications describing BACE1 as the enzyme that produces A\u03b2 and summarizing development of BACE1 inhibitors (context for mechanism and CADRO mapping). \ue200cite\ue202turn0search3\ue202turn0search5\ue201"
    ]
}